Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
- PMID: 18338393
- DOI: 10.1002/humu.20676
Gaucher disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA)
Abstract
Gaucher disease (GD) is an autosomal recessive disorder caused by the deficiency of glucocerebrosidase, a lysosomal enzyme that catalyses the hydrolysis of the glycolipid glucocerebroside to ceramide and glucose. Lysosomal storage of the substrate in cells of the reticuloendothelial system leads to multisystemic manifestations, including involvement of the liver, spleen, bone marrow, lungs, and nervous system. Patients with GD have highly variable presentations and symptoms that, in many cases, do not correlate well with specific genotypes. Almost 300 unique mutations have been reported in the glucocerebrosidase gene (GBA), with a distribution that spans the gene. These include 203 missense mutations, 18 nonsense mutations, 36 small insertions or deletions that lead to either frameshifts or in-frame alterations, 14 splice junction mutations, and 13 complex alleles carrying two or more mutations in cis. Recombination events with a highly homologous pseudogene downstream of the GBA locus also have been identified, resulting from gene conversion, fusion, or duplication. In this review we discuss the spectrum of GBA mutations and their distribution in the patient population, evolutionary conservation, clinical presentations, and how they may affect the structure and function of glucocerebrosidase.
Similar articles
-
Molecular analysis of Turkish Gaucher disease patients: identification of novel mutations in glucocerebrosidase (GBA) gene.Eur J Med Genet. 2008 Jul-Aug;51(4):315-21. doi: 10.1016/j.ejmg.2008.02.004. Epub 2008 Mar 4. Eur J Med Genet. 2008. PMID: 18586596
-
Glucocerebrosidase gene mutations in patients with type 2 Gaucher disease.Hum Mutat. 2000;15(2):181-8. doi: 10.1002/(SICI)1098-1004(200002)15:2<181::AID-HUMU7>3.0.CO;2-S. Hum Mutat. 2000. PMID: 10649495 Review.
-
An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.Proteins. 2008 Feb 15;70(3):882-91. doi: 10.1002/prot.21554. Proteins. 2008. PMID: 17803231
-
The identification of eight novel glucocerebrosidase (GBA) mutations in patients with Gaucher disease.Hum Mutat. 2002 Apr;19(4):458-9. doi: 10.1002/humu.9024. Hum Mutat. 2002. PMID: 11933202
-
Gaucher disease: complexity in a "simple" disorder.Mol Genet Metab. 2004 Sep-Oct;83(1-2):6-15. doi: 10.1016/j.ymgme.2004.08.015. Mol Genet Metab. 2004. PMID: 15464415 Review.
Cited by
-
The annotation of GBA1 has been concealed by its protein-coding pseudogene GBAP1.Sci Adv. 2024 Jun 28;10(26):eadk1296. doi: 10.1126/sciadv.adk1296. Epub 2024 Jun 26. Sci Adv. 2024. PMID: 38924406 Free PMC article.
-
A Large-Scale Full GBA1 Gene Screening in Parkinson's Disease in the Netherlands.Mov Disord. 2020 Sep;35(9):1667-1674. doi: 10.1002/mds.28112. Epub 2020 Jul 2. Mov Disord. 2020. PMID: 32618053 Free PMC article.
-
Precision medicine in Parkinson's disease patients with LRRK2 and GBA risk variants - Let's get even more personal.Transl Neurodegener. 2020 Oct 16;9(1):39. doi: 10.1186/s40035-020-00218-x. Transl Neurodegener. 2020. PMID: 33066808 Free PMC article. Review.
-
Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review.Biology (Basel). 2022 Sep 2;11(9):1308. doi: 10.3390/biology11091308. Biology (Basel). 2022. PMID: 36138787 Free PMC article. Review.
-
Treatment Efficiency in Gaucher Patients Can Reliably Be Monitored by Quantification of Lyso-Gb1 Concentrations in Dried Blood Spots.Int J Mol Sci. 2020 Jun 27;21(13):4577. doi: 10.3390/ijms21134577. Int J Mol Sci. 2020. PMID: 32605119 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical